Oncology Clinic Companion

The Oncology Clinic Companion is an educational initiative for the entire cancer care team.

[Oncology Clinic Companion @OncClinicComp]

Delighted to see EIOCCs #MedEd initiative appear in @JECME! Feasibility of Integrating a Mobile Decision-Support App into a Multicomponent CME Initiative: Developing Clinician Competence at the Point of Care:https://t.co/rmUtKNzK0L @EuropeanCME @cpdcontent @ONCOassist #ImmunoOnc

[Oncology Clinic Companion @OncClinicComp]

Delighted to be the CME partner for this important launch during #ASCO22

[ONCOassist® | The go-to oncology app @ONCOassist]

We are pleased to announce the launch of our new NSCLC ONCOdriver Therapy Tool. This tool integrates guidelines on testing & treatment for driver mutations in NSCLC, beginning with #ALK and #ROS1. Find CME-certified companion resources at https://t.co/zgv3ae0cdF #OncoAlert

[NatureRevClinOncol @NatRevClinOncol]

In a first-in-human phase I study of the anti–TIGIT antibody vibostolimab as monotherapy or in combination with pembrolizumab, treatment seemed well tolerated. ORRs were 0-26%, being highest with the combination in pts with anti-PD-1/PD-L1–naïve NSCLC: https://t.co/JHyXdYgLJT

[Journal for ImmunoTherapy of Cancer @jitcancer]

Does tumor burden impact tumor immunity and response to immunotherapy? Important review on this topic @NatRevClinOncol https://t.co/HVb5m1infa #JITC SM @MosheOrnsteinMD

[JAMA Oncology @JAMAOnc]

In a randomized 1L phase 3 (eXalt3) trial in #ALK-positive #NSCLC, PFS was significantly longer with ensartinib vs crizotinib (NR vs 12.7 months, HR=0.45) by BIRC with a favorable safety profile. CNS ORR was 64% with ensartinib vs 21% with crizotinib https://t.co/MjH8qqaGdx #LCSM

[NatureRevClinOncol @NatRevClinOncol]

In a phase II study of the ATR inhibitor ceralasertib plus durvalumab in pts with advanced-stage melanoma with progression on prior anti-PD-1 therapy, the ORR was 31%, the DCR was 63.3%, mPFS was 7.1 months & mOS was 14.2 months: https://t.co/g1nzQEU847 #melsm #ImmunoOnc

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab https://t.co/jgxcf3Wxbr @DrBetofMDPhD @wolchokj @MPostow

[Oncology Clinic Companion @OncClinicComp]

Neoadjuvant PD1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal #cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial: https://t.co/EeYlXSuyGz

[Cancers MDPI @Cancers_MDPI]

📣Today we share #Review "Overview of Immune Checkpoint Inhibitors Therapy for #Hepatocellular #Carcinoma, and The https://t.co/kcwuOgeegs Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice"
Find Full-Text on👉https://t.co/zoyJunBWTi

[Oncology Clinic Companion @OncClinicComp]

The Use of #Mobile Applications for the Diagnosis and Treatment of Tumors in Orthopaedic #Oncology – a #SystematicReview: https://t.co/ZD3qdd39Hh #cancer #Orthopaedics

[NatureRevClinOncol @NatRevClinOncol]

In a phase III trial in 982 men with androgen signalling inhibitor-naive mCRPC, adding apalutamide to abiraterone–prednisone improved rPFS (median 24 vs 16.6 months; HR 0.70; P<00001), but not mOS (36.2 vs 33.7 months; HR 0.95; P=0.50): https://t.co/sb9qJsaoSF #PCSM #uroonc

[JAMA Oncology @JAMAOnc]

Cancer programs with high use of neoadjuvant chemotherapy for patients with advanced ovarian cancer achieve similar gains median survival and lager improvements in short-term mortality compared with programs with low use https://t.co/yZu3g92xxN #GynCSM

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach https://t.co/bG34Ejc725 @TomasNeilan

[Annals of Oncology @Annals_Oncology]

Grade 2 is the grey zone for treatment decisions in early #BreastCancer . Could the development of a model using deep learning allow an improved risk stratification?
Check out this #openaccess article in @Annals_Oncology:
https://t.co/VI5WY4AVKu
#bcsm @rantalainen @ki_meb_biostat

[Oncology Clinic Companion @OncClinicComp]

Therapeutic drug monitoring in #oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for #imatinib therapy: https://t.co/tR8UZUcsID @IATDMCT @OncologyAdvance #cancer #guidelines #MedTwitter #healthcare #medicine

[Oncology Clinic Companion @OncClinicComp]

Access to #cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional #survey: https://t.co/UAqlHHuYAx #oncology #medicine #treatment #MedTwitter @TheLancetOncol

[OncoViews @OncoViews]

Results from the STIMULI trial by @peters_solange, @MartinReck2, and colleagues are now online in @Annals_Oncology.

Results showed no improvement for PFS & OS with nivolumab-ipilimumab consolidation after chemo-radiotherapy in limited disease #SCLC

➡️ https://t.co/3iN3x1oxNp

[ESMO - Eur. Oncology @myESMO]

#ESMOasiaweek21: registration is open & free of charge! A week of top events ✅ ESMO Asia Highlights of the Year Meeting ✅ Pan Asian adapted Guidelines lectures ✅Policy sessions ✅ #VirtualPlenary sessions ✅ Preceptorship courses 👉https://t.co/LeoppZKMjs

[JAMA Oncology @JAMAOnc]

Study found ivosidenib is well tolerated and resulted in a favorable OS benefit vs placebo in advanced IDH1mutated cholangiocarcinoma, revealing a compelling clinical benefit of ivosidenib in this clinical setting https://t.co/Ol9vRwY4RD #GICSM

[JAMA Oncology @JAMAOnc]

Cohort study of 634 patients w metastatic #ProstateCancer showed distinct molecular patterns assoc'd w luminal & basal subtypes, & subtypes were prognostic, with stronger benefit from androgen inhibitor therapies in pts w luminal subtype https://t.co/CjNzlrpjpe #PCSM

[JAMA Oncology @JAMAOnc]

Study found ivosidenib is well tolerated and resulted in a favorable OS benefit vs placebo in advanced IDH1mutated cholangiocarcinoma, revealing a compelling clinical benefit of ivosidenib in this clinical setting https://t.co/A5ZLeZRPhi #GICSM